Mimedx Group, Inc. revenue
Mimedx Group, Inc.'s revenue was $419m in fiscal 2025, up 20.0% on the year before. Since fiscal 2010 ($788,874) it has grown at a compound 76.9% a year. Over the last twelve months it was $304m.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 8 | 222 | 321 | 359 | 299 | 248 | 242 | 268 | 321 | 349 | 419 | 304 |
| Growth on the year before | — | +883.7% | +>999% | +44.8% | +11.8% | −16.7% | −17.0% | −2.5% | +10.7% | +20.0% | +8.5% | +20.0% | — |
| Gross profit | — | 4 | 191 | 286 | 323 | 256 | 209 | 202 | 220 | 267 | 289 | 346 | 235 |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Wound | $276M | 66.0% | ▲ 19.6% |
| Surgical | $142M | 34.0% | ▲ 20.7% |
From Mimedx Group, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Mimedx Group, Inc. | $304m | -22.8% | -0.6% |
| Organogenesis Holdings Inc. | $457m | 6.5% | 0.0% |
| UFP Technologies Inc | $632m | 7.3% | 17.8% |
| Orasure Technologies Inc | $112m | -18.9% | -38.4% |
| Embecta Corp. | $1.02bn | -7.6% | -2.9% |
| ICU Medical Inc | $2.16bn | -9.0% | -2.0% |
Compare with peers
- Organogenesis Holdings Inc. revenue
- UFP Technologies Inc revenue
- Orasure Technologies Inc revenue
- Embecta Corp. revenue
- ICU Medical Inc revenue
Head to head: MDXG vs ORGOMDXG vs UFPTMDXG vs OSUR
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies